arGEN-X BV - Product Pipeline Review - 2016

  • ID: 3846532
  • Company Profile
  • 42 pages
  • Global Markets Direct
1 of 4
arGEN-X BV - Product Pipeline Review - 2016

Summary

‘arGEN-X BV - Product Pipeline Review - 2016’, provides an overview of the arGEN-X BV’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by arGEN-X BV, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of arGEN-X BV
- The report provides overview of arGEN-X BV including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses arGEN-X BV’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features arGEN-X BV’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate arGEN-X BV’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for arGEN-X BV
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding arGEN-X BV’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

arGEN-X BV Snapshot

arGEN-X BV Overview

Key Information

Key Facts

arGEN-X BV - Research and Development Overview

Key Therapeutic Areas

arGEN-X BV - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

arGEN-X BV - Pipeline Products Glance

arGEN-X BV - Clinical Stage Pipeline Products

Phase I Products/Combination Treatment Modalities

arGEN-X BV - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

arGEN-X BV - Drug Profiles

ARGX-110

Product Description

Mechanism of Action

R&D Progress

ARGX-111

Product Description

Mechanism of Action

R&D Progress

ARGX-113

Product Description

Mechanism of Action

R&D Progress

ARGX-112

Product Description

Mechanism of Action

R&D Progress

ARGX-115

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies for Cancer, Immunology and Metabolic Disorders

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody for Skin Inflammation

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies to Block Nav1.7 for Chronic Pain

Product Description

Mechanism of Action

R&D Progress

arGEN-X BV - Pipeline Analysis

arGEN-X BV - Pipeline Products by Target

arGEN-X BV - Pipeline Products by Route of Administration

arGEN-X BV - Pipeline Products by Molecule Type

arGEN-X BV - Pipeline Products by Mechanism of Action

arGEN-X BV - Recent Pipeline Updates

arGEN-X BV - Dormant Projects

arGEN-X BV - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

arGEN-X BV, Key Information

arGEN-X BV, Key Facts

arGEN-X BV - Pipeline by Indication, 2016

arGEN-X BV - Pipeline by Stage of Development, 2016

arGEN-X BV - Monotherapy Products in Pipeline, 2016

arGEN-X BV - Partnered Products in Pipeline, 2016

arGEN-X BV - Partnered Products/ Combination Treatment Modalities, 2016

arGEN-X BV - Out-Licensed Products in Pipeline, 2016

arGEN-X BV - Out-Licensed Products/ Combination Treatment Modalities, 2016

arGEN-X BV - Phase I, 2016

arGEN-X BV - Preclinical, 2016

arGEN-X BV - Discovery, 2016

arGEN-X BV - Pipeline by Target, 2016

arGEN-X BV - Pipeline by Route of Administration, 2016

arGEN-X BV - Pipeline by Molecule Type, 2016

arGEN-X BV - Pipeline Products by Mechanism of Action, 2016

arGEN-X BV - Recent Pipeline Updates, 2016

arGEN-X BV - Dormant Developmental Projects,2016

arGEN-X BV, Subsidiaries 40List of Figures

arGEN-X BV - Pipeline by Top 10 Indication, 2016

arGEN-X BV - Pipeline by Stage of Development, 2016

arGEN-X BV - Monotherapy Products in Pipeline, 2016

arGEN-X BV - Partnered Products in Pipeline, 2016

arGEN-X BV - Out-Licensed Products in Pipeline, 2016

arGEN-X BV - Pipeline by Target, 2016

arGEN-X BV - Pipeline by Route of Administration, 2016

arGEN-X BV - Pipeline by Molecule Type, 2016

arGEN-X BV - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll